An integrative molecular tumor board approach to pediatric B atypical choroid plexus papilloma with an equivocal residual lesion: a case report
This case report describes a 2.6-year-old boy with pediatric subgroup B atypical choroid plexus papilloma who achieved durable radiological remission after an integrative molecular tumor board approach combined DNA methylation profiling, precision oncology, and repeated maximal safe resections to navigate diagnostic discordance and aggressive tumor progression.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Inside the brain, a delicate network of tissue produces the fluid that cushions and nourishes the central nervous system. Occasionally, cells in this network grow out of control, forming rare tumors known as choroid plexus tumors. These growths are most common in very young children and can be categorized by how they look under a microscope and how they behave. Some are slow-growing and benign, while others are more aggressive and dangerous. For decades, doctors have relied on visual inspection of the tumor cells to decide on a treatment plan, but this method can sometimes be unclear. A newer tool, which examines the chemical tags on the tumor's DNA, has begun to offer a sharper picture, sorting these tumors into groups that predict their future behavior more accurately. This distinction is vital because it helps doctors decide whether a child needs only surgery, or if they also require chemotherapy or radiation, treatments that carry significant risks for a developing brain.
The story of a two-year-old boy from Germany illustrates the complexity of treating these rare tumors when the signs are mixed. The child arrived with symptoms of a blocked brain, including vomiting and irritability, caused by a large mass in the left side of his brain's fluid-filled space. Surgeons removed as much of the tumor as safely possible, but a piece remained. When pathologists examined the tissue, they could not agree on what it was; one team saw a benign growth, while another saw signs of a more dangerous, atypical version. To resolve this, the team turned to the DNA methylation test, which confirmed the tumor belonged to a high-risk group known as pediatric subgroup B. Despite this warning, the doctors chose to wait and watch, hoping the child's young age and the tumor's initial appearance meant they could avoid the harsh side effects of chemotherapy.
This strategy of close observation did not last long. Within three months, the remaining tumor had grown significantly. The medical team returned to the operating room, performing two more surgeries to remove the bulk of the mass. With each operation, the tumor revealed itself to be more aggressive than the first look suggested, showing features that bordered on cancer. The doctors then turned to a comprehensive molecular analysis to find a weakness in the tumor that drugs could target. They tested the tumor cells against a wide panel of seventy-nine different medicines in a laboratory setting. The results were sobering: the tumor showed broad resistance to standard chemotherapy drugs, including the very agents typically used for this type of cancer. It did not respond to the usual treatments, and no specific genetic target was found that could be attacked with a precision drug.
Faced with a tumor that was growing quickly and ignoring standard medicines, the team had to make a difficult choice. They decided to try a different, more intensive chemotherapy regimen, one that included powerful drugs designed to damage the DNA of dividing cells, but they stopped short of using the most extreme doses that would require a bone marrow transplant. The treatment began, but the tumor did not stop. During the second cycle of chemotherapy, a new, suspicious line of enhancement appeared on the MRI scans along the path where the surgeons had cut. It was unclear whether this was a scar from the surgery or a new trail of tumor cells spreading through the brain. The chemotherapy was halted, and the child underwent a fifth surgery. This time, the surgeons removed the remaining mass and the entire suspicious track of tissue.
The final examination confirmed that the tumor cells were still present in the original site and along the surgical path, but they were not growing rapidly. With the bulk of the disease gone and the remaining piece too small to remove safely, the doctors made a final, individualized decision. They chose to stop all active treatment and return to a strategy of careful monitoring, as the significance of the tiny remaining area was uncertain. Over the next thirty months, the child remained healthy and developed normally. The mysterious line of enhancement seen on the scans faded away, leaving only the faint, non-specific marks of past surgery. The child remains in remission, a result achieved not by a single miracle drug, but by a relentless cycle of precise surgery, deep molecular testing, and a willingness to adapt the treatment plan as the disease revealed its true nature.
This case highlights that for some rare pediatric brain tumors, the most effective tool remains the surgeon's scalpel, guided by modern molecular insights. While the standard chemotherapy drugs failed to control this specific tumor, the team's ability to integrate genetic data with repeated, safe surgical removal allowed them to spare the child from unnecessary long-term toxicity. The journey underscores that when a tumor behaves unpredictably, a rigid adherence to standard protocols may not be enough. Instead, a flexible, multidisciplinary approach that combines the latest genetic science with careful clinical judgment offers the best chance for a durable cure. The child's continued health suggests that for these difficult cases, the path forward lies in individualized care rather than a one-size-fits-all solution.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.